26 completed. 26 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 26 |
| Phase 2 | 1 | Completed 1 |
Follow Cough: new trials by email Literature Review of Cough trials Research Report on Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Reconyl in Acute Cough Treatment Reconyl, Placebo of Reconyl - Cough | Phase 3 | Completed | Dexa Medica Group | 144 | 2025-06-26 | 2026-02-19 |
| A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Cough, Refractory Chronic Cough | Phase 3 | Completed | Bellus Health Inc. - a GSK company | 957 | 2022-10-25 | 2026-07-14 |
| Efficacy of SLN Block for Chronic Cough Superior laryngeal nerve block, Injection of placebo (saline), Injection of steroid-lidocaine mixture - Cough, Superior Laryngeal Nerve Block | Phase 3 | Completed | Medical University of South Carolina | 17 | 2020-07-22 | 2025-10-23 |
| Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) Gefapixant, Placebo - Chronic Cough | Phase 3 | Completed | Merck Sharp & Dohme LLC | 419 | 2020-05-21 | 2023-05-16 |
| Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) Gefapixant, Placebo - Chronic Cough | Phase 3 | Completed | Merck Sharp & Dohme LLC | 376 | 2020-05-10 | 2024-11-05 |
| A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg, placebo - Respiratory Tract Diseases, Abnormal Mucus Secretions | Phase 3 | Completed | Zambon SpA | 333 | 2019-06-25 | 2025-09-05 |
| A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension Gefapixant 45 mg twice daily (BID), Gefapixant 15 mg BID, Placebo - Chronic Cough | Phase 3 | Completed | Merck Sharp & Dohme LLC | 161 | 2019-05-17 | 2024-01-12 |
| Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study) Azithromycin, Amoxicillin - Tuberculosis, Respiratory Tract Infections | Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 1583 | 2019-02-25 | 2021-04-28 |
| A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) Gefapixant, Placebo - Chronic Cough | Phase 3 | Completed | Merck Sharp & Dohme LLC | 175 | 2018-10-31 | 2021-11-01 |
| A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030) Placebo, Gefapixant 15 mg BID, Gefapixant 45 mg BID - Chronic Cough | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1317 | 2018-03-15 | 2021-09-02 |
| A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027) Placebo, Gefapixant - Chronic Cough | Phase 3 | Completed | Merck Sharp & Dohme LLC | 732 | 2018-03-14 | 2021-06-16 |
| Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough Levopront® syrup 30 mg/5 ml, Libexin® - Cough | Phase 3 | Completed | Dompé Farmaceutici S.p.A | 184 | 2016-11-09 | 2024-04-16 |
| A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy 1% lignocaine, 2% lignocaine - Lung Cancer, Tuberculosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 500 | 2014-05-01 | 2014-12-30 |
| Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316 favipiravir, Placebo - Influenza | Phase 3 | Completed | MDVI, LLC | 860 | 2014-01-01 | 2015-11-11 |
| Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults favipiravir, placebo - Influenza | Phase 3 | Completed | MDVI, LLC | 1161 | 2013-12-01 | 2015-11-11 |
| Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment Syrup of oxomemazine, guaifenesin and potassium iodate, Syrup of guaifenesin - Cough | Phase 3 | Completed | EMS | 260 | 2012-10-01 | 2019-04-17 |
| Study of the Safety and Effectiveness of BC1036 Capsules to Treat Frequent Long-Term Cough BC1036 - Cough | Phase 3 | Completed | Respicopea Limited | 288 | 2012-07-01 | 2013-08-02 |
| Effect of Betamethasone Gel and Lidocaine Jelly on Sore Throat, Cough and Hoarseness of betamethasone gel, lidocaine jelly, distilled water - Sore Throat, Cough | Phase 3 | Completed | Tehran University of Medical Sciences | 99 | 2012-03-01 | 2014-04-15 |
| Evaluation of the Efficacy and Tolerability of ABO/MEG-B-09 in Children With Acute Cough AboMeg-B-09, Placebo - Cough | Phase 3 | Completed | Aboca Spa Societa' Agricola | 102 | 2010-10-01 | 2014-12-02 |
| Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher Theobromine 300mg, Levodropropizine 10mg - Acute Bronchitis | Phase 3 | Completed | Ahn-Gook Pharmaceuticals Co.,Ltd | 332 | 2010-05-01 | 2011-08-15 |
Showing 20 of 26. Sign in to see all of them.
Chronic Cough (9) · Influenza, Human (5) · Headache (4) · Pharyngitis (4) · Respiratory Tract Diseases (4) · Fatigue (3) · Fever (3) · Nasal Obstruction (3) · Respiration Disorders (3) · Signs and Symptoms, Respiratory (3) · Bronchitis (2) · Bronchitis, Chronic (2) · Common Cold (2) · Hoarseness (2)
Pathological Conditions, Signs and Symptoms (26) · Signs and Symptoms (24) · Respiration Disorders (23) · Signs and Symptoms, Respiratory (23) · Respiratory Tract Diseases (22) · Infections (12) · Respiratory Tract Infections (10) · Lung Diseases (8) · Neurologic Manifestations (6) · Bronchial Diseases (5) · Lung Diseases, Obstructive (5) · Orthomyxoviridae Infections (5) · Otorhinolaryngologic Diseases (5) · RNA Virus Infections (5) · Virus Diseases (5)
Gefapixant (6) · Azithromycin (2) · BID protein, human (2) · Lidocaine (2) · Theobromine (2) · dipropizine (2) · favipiravir (2) · Acetylcysteine (1) · Ambroxol (1) · Amoxicillin (1) · BLU-5937 (1) · Epinephrine (1) · Guaifenesin (1) · Laryngeal Masks (1) · Sodium Chloride (1)
Merck Sharp & Dohme LLC (6) · Ahn-Gook Pharmaceuticals Co.,Ltd (2) · MDVI, LLC (2) · Aboca Spa Societa' Agricola (1) · Bellus Health Inc. - a GSK company (1) · BioCryst Pharmaceuticals (1) · Dexa Medica Group (1) · Dompé Farmaceutici S.p.A (1) · EMS (1) · Isala (1) · Johns Hopkins University (1) · London School of Hygiene and Tropical Medicine (1) · Medical University of South Carolina (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Respicopea Limited (1)
United States (11) · Canada (7) · United Kingdom (6) · Colombia (5) · Peru (5) · Poland (5) · South Korea (5) · Spain (5) · Ukraine (5) · Argentina (4) · Guatemala (4) · Hungary (4) · Israel (4) · Russia (4) · Turkey (Türkiye) (4)
Carol Epstein, MD (2) · Alan Jackson, MB, BS (1) · Alun George, MA MBBS, DRCOG, DCH, MRCGP (1) · Alyn Morice, BA(Hons) MB.B.Chir MA FRCP (1) · Arienne de Jong, PhD (1) · Bernard Higgins, MB ChB, MRCP, MD (1) · Choon-Taek Lee, MD, PhD (1) · Chris Strang, MB BS, D. Obst, RCOG M (1) · Chul-min Ahn, MD, PhD (1) · Courtney Tipton (1) · Damien McNally, MB,BCh,BAO,DRCOG,DMH,MRCGP (1) · Fan Chung, MB, BS, MD, FRCP, DSc (PI) (1) · Federico Saibene, MD (1) · Felipe Pinho, MD (1)
PMID 35248186, PMID 35569802, PMID 35639525, PMID 22230731, PMID 22986377, PMID 23985625, PMID 24229360, PMID 25811287, PMID 25985845, PMID 28839984, PMID 32217561, PMID 35752582, PMID 36879087, PMID 36925176, PMID 39222649, PMID 39706278
2017 (2), 2019 (2)